Hong Kong and the biotech race: A latecomer’s trump card
For global biotech professionals and investors, the contrast between Hong Kong and Singapore offers a cautionary tale—and a reminder that institutional infrastructure, talent pipelines, and…
For global biotech professionals and investors, the contrast between Hong Kong and Singapore offers a cautionary tale—and a reminder that institutional infrastructure, talent pipelines, and…
For global investors, researchers, and strategic planners, Beijing’s new five-year plan signals a definitive state-backed shift to turn quantum communication and AI into core drivers…
For China’s rapidly evolving AI sector, the cautionary signals from Silicon Valley offer a strategic preview of the human-capital challenges that lie ahead — and…
As competition over artificial intelligence shifts from laboratory breakthroughs to industrial control, the question is no longer which model is smarter, but which economy can…
A new wave of regulatory caution from Beijing is redefining the pathway for Chinese tech and biotech firms seeking offshore listings, with significant implications for…
China’s push to reduce reliance on proprietary chip architectures gains fresh momentum as Alibaba’s Damo Academy unveils a processor purpose-built for the next wave of…
The very technology driving a historic investment wave is simultaneously creating a paradox of job displacement, forcing a global conversation on the future of work…
The competition to lead in artificial intelligence is increasingly defined by deployment, integration, and the strategic control of industrial ecosystems, not merely by theoretical breakthroughs.…
The regulatory shift signals a maturing, more cautious approach to capital markets, prioritizing oversight over unbridled growth in sensitive sectors. A significant shift is underway…
Alibaba’s latest RISC-V processor signals a strategic push to build a domestic, open-source hardware ecosystem, aiming to reduce reliance on proprietary architectures and capture the…